Repligen Co. (RGEN) Shares Sold by First Mercantile Trust Co.

First Mercantile Trust Co. trimmed its position in shares of Repligen Co. (NASDAQ:RGEN) by 14.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,335 shares of the biotechnology company’s stock after selling 395 shares during the quarter. First Mercantile Trust Co.’s holdings in Repligen were worth $123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Hawaiian Bank bought a new position in shares of Repligen during the 4th quarter valued at $28,000. Oppenheimer Asset Management Inc. bought a new position in shares of Repligen during the 4th quarter valued at $110,000. Pacer Advisors Inc. bought a new position in shares of Repligen during the 3rd quarter valued at $116,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Repligen by 20.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,687 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 462 shares during the period. Finally, Seven Eight Capital LP bought a new position in shares of Repligen during the 3rd quarter valued at $217,000. 97.15% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:RGEN opened at $60.11 on Wednesday. The firm has a market capitalization of $2.60 billion, a PE ratio of 87.12, a P/E/G ratio of 3.85 and a beta of 1.04. Repligen Co. has a one year low of $31.38 and a one year high of $70.50.

Several research firms have recently weighed in on RGEN. Zacks Investment Research cut Repligen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub cut Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, CL King upgraded Repligen from a “neutral” rating to a “buy” rating in a research note on Monday, December 17th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Repligen has a consensus rating of “Buy” and an average price target of $59.20.

In other news, CFO Jon Snodgres sold 31,753 shares of the company’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $63.49, for a total value of $2,015,997.97. Following the completion of the sale, the chief financial officer now directly owns 32,344 shares in the company, valued at approximately $2,053,520.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.40% of the company’s stock.

WARNING: “Repligen Co. (RGEN) Shares Sold by First Mercantile Trust Co.” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2019/02/13/repligen-co-rgen-shares-sold-by-first-mercantile-trust-co.html.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: What is a Lock-Up Period?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit